Editas Q1 net loss $25M ($0.26/share); EDIT-401 on track for human data by year-end

Editas Medicine, Inc.

2026-Q1 EPS reported -$0.26 vs consensus -$0.27 ▲ beat (+3.3%)

Net loss of $25.0M ($0.26 per share) vs. $76.1M ($0.92) in Q1 2025; no restructuring charges this quarter.
Cash and equivalents $123.6M as of March 31; expected to fund operations into Q3 2027.
R&D expenses down 34% YoY to $17.6M due to reni-cel discontinuation and headcount reduction.
EDIT-401 preclinical shows >90% mean LDL-C reduction; first-in-human trial for HeFH expected in H2 2026 with proof-of-concept data by year-end.
USPTO reaffirmed Broad Institute's priority in CRISPR/Cas9 patent interference, supporting Editas' licensed IP.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Editas Medicine, Inc. reported the first quarter 2026 results: net income net loss attributable to common stockholders was $25.0 million , or $0.26 per share.

Period: the first quarter 2026
Net income: net loss attributable to common stockholders was $25.0 million , or $0.26 per share
Result: reported results

Exact text from the filing

expenditure requirements into the third quarter of 2027. First Quarter 2026 • For the three months ended March 31, 2026 , net loss attributable to common stockholders was $25.0 million , or $0.26 per share, compared to net loss of $76.1 million , or $0.92 per share, for the same period in 2025 . • Collaboration and other research and development revenues

View on SEC.gov

Browse all earnings releases →

Editas Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001650664-26-000043

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.